Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=keywords" }, "data": [ { "type": "Grant", "id": "5008", "attributes": { "award_id": "5R01AI148166-03", "title": "Role of Diabetes in MERS Coronavirus Pathogenesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 17957, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-16", "end_date": "2024-05-31", "award_amount": 552435, "principal_investigator": { "id": 17958, "first_name": "Matthew Bryan", "last_name": "Frieman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Here we seek to identify the role of diabetes in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) pathogenesis. MERS-CoV emerged in 2012 in Saudi Arabia leading to over 2200 infections with a ~35% case fatality rate. The majority of lethal MERS-CoV infections are associated with a comorbidity, with diabetes as the top comorbidity. We have found that MERS-CoV pathogenesis is exacerbated in a mouse with pre-existing diabetes. We will determine the mechanism for this enhanced disease by determining the role of the changes in lung architecture, and immune response. In Aim1 we will determine whether accessibility of the Type 2 alveolar cells, the target cells for MERS-CoV in the alveoli, is increased in diabetic mice compared to normal mice. Our data suggests that at the earliest points of infection, the alveoli are highly susceptible to MERS- CoV but normal mouse Type 2 alveolar cells are not. We will evaluate the mucus and architecture of the lungs to determine if there is a difference that could explain the differential infection. In Aim 2, we will determine if the immune response in diabetic mice is different than normal mice. A difference in the immune response, especially innate immune response, could explain the susceptibility differences in diabetic and normal mice. In Aim 3 we will determine whether therapeutics that are effective in normal mice are deficient in diabetic mice with the goal of altering those therapeutics in the future for more effective therapies for comorbid patients. Together this proposal will determine why diabetic mice and potentially humans are highly susceptible to MERS-CoV.", "keywords": [ "Alveolar", "Alveolar Cell", "Alveolus", "Animal Model", "Antiviral Agents", "Antiviral Therapy", "Architecture", "Carbohydrates", "Case Fatality Rates", "Case Study", "Cell surface", "Cells", "Cessation of life", "Clinical", "Complex Mixtures", "Coronavirus", "Coronavirus Infections", "Data", "Diabetes Mellitus", "Diabetic mouse", "Diet", "Disease", "Disease Outbreaks", "Disease Outcome", "Effectiveness", "Exhibits", "Future", "Glare", "Goals", "Health Personnel", "Heart Diseases", "High Fat Diet", "Human", "Immune", "Immune response", "Immunosuppression", "Infection", "Inflammatory", "Innate Immune Response", "Kidney Failure", "Kinetics", "Knowledge", "Lead", "Link", "Lung", "Lung diseases", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Monoclonal Antibodies", "Morbidity - disease rate", "Mucous Membrane", "Mucous body substance", "Mus", "Non-Insulin-Dependent Diabetes Mellitus", "Pathogenesis", "Pathogenicity", "Pathway interactions", "Patients", "Persons", "Poly I-C", "Predisposition", "Production", "Proteins", "Public Health", "Pulmonary Inflammation", "Respiratory System", "Respiratory Tract Infections", "Risk", "Role", "Saudi Arabia", "South Korea", "Structure", "Surface", "Therapeutic", "Time", "Treatment Efficacy", "Vaccines", "Virion", "Virus", "Virus Diseases", "Work", "anti-viral efficacy", "chemokine", "comorbidity", "comparative", "cytokine", "diabetic", "diabetic patient", "effective therapy", "experimental study", "in vivo", "influenza virus vaccine", "microbial", "mortality", "mouse model", "novel", "pathogen", "permissiveness", "receptor", "respiratory infection virus", "respiratory virus", "response", "targeted treatment", "therapeutically effective" ], "approved": true } }, { "type": "Grant", "id": "5683", "attributes": { "award_id": "5R01AI148166-02", "title": "Role of Diabetes in MERS Coronavirus Pathogenesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19628, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-16", "end_date": "2024-05-31", "award_amount": 556863, "principal_investigator": { "id": 19629, "first_name": "Matthew Bryan", "last_name": "Frieman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Here we seek to identify the role of diabetes in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) pathogenesis. MERS-CoV emerged in 2012 in Saudi Arabia leading to over 2200 infections with a ~35% case fatality rate. The majority of lethal MERS-CoV infections are associated with a comorbidity, with diabetes as the top comorbidity. We have found that MERS-CoV pathogenesis is exacerbated in a mouse with pre-existing diabetes. We will determine the mechanism for this enhanced disease by determining the role of the changes in lung architecture, and immune response. In Aim1 we will determine whether accessibility of the Type 2 alveolar cells, the target cells for MERS-CoV in the alveoli, is increased in diabetic mice compared to normal mice. Our data suggests that at the earliest points of infection, the alveoli are highly susceptible to MERS- CoV but normal mouse Type 2 alveolar cells are not. We will evaluate the mucus and architecture of the lungs to determine if there is a difference that could explain the differential infection. In Aim 2, we will determine if the immune response in diabetic mice is different than normal mice. A difference in the immune response, especially innate immune response, could explain the susceptibility differences in diabetic and normal mice. In Aim 3 we will determine whether therapeutics that are effective in normal mice are deficient in diabetic mice with the goal of altering those therapeutics in the future for more effective therapies for comorbid patients. Together this proposal will determine why diabetic mice and potentially humans are highly susceptible to MERS-CoV.", "keywords": [ "Alveolar", "Alveolar Cell", "Animal Model", "Antiviral Agents", "Antiviral Therapy", "Architecture", "Carbohydrates", "Case Fatality Rates", "Case Study", "Cell surface", "Cells", "Cessation of life", "Clinical", "Complex Mixtures", "Coronavirus", "Coronavirus Infections", "Data", "Diabetes Mellitus", "Diabetic mouse", "Diet", "Disease", "Disease Outbreaks", "Disease Outcome", "Effectiveness", "Exhibits", "Future", "Glare", "Goals", "Health Personnel", "Heart Diseases", "High Fat Diet", "Human", "Immune", "Immune response", "Immunosuppression", "Infection", "Inflammatory", "Innate Immune Response", "Kidney Failure", "Kinetics", "Knowledge", "Lead", "Link", "Lung", "Lung Inflammation", "Lung diseases", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Monoclonal Antibodies", "Morbidity - disease rate", "Mucous Membrane", "Mucous body substance", "Mus", "Non-Insulin-Dependent Diabetes Mellitus", "Pathogenesis", "Pathogenicity", "Pathway interactions", "Patients", "Persons", "Poly I-C", "Predisposition", "Production", "Proteins", "Public Health", "Respiratory System", "Risk", "Role", "Saudi Arabia", "South Korea", "Structure", "Surface", "Therapeutic", "Time", "Treatment Efficacy", "Vaccines", "Virion", "Virus", "Virus Diseases", "Work", "anti-viral efficacy", "chemokine", "comorbidity", "comparative", "cytokine", "diabetic", "diabetic patient", "effective therapy", "experimental study", "in vivo", "influenza virus vaccine", "microbial", "mortality", "mouse model", "novel", "pathogen", "permissiveness", "receptor", "respiratory infection virus", "respiratory virus", "response", "targeted treatment", "therapeutically effective" ], "approved": true } }, { "type": "Grant", "id": "6503", "attributes": { "award_id": "1R01AI148166-01A1", "title": "Role of Diabetes in MERS Coronavirus Pathogenesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21804, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-16", "end_date": "2024-05-31", "award_amount": 609387, "principal_investigator": { "id": 21805, "first_name": "Matthew Bryan", "last_name": "Frieman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Here we seek to identify the role of diabetes in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) pathogenesis. MERS-CoV emerged in 2012 in Saudi Arabia leading to over 2200 infections with a ~35% case fatality rate. The majority of lethal MERS-CoV infections are associated with a comorbidity, with diabetes as the top comorbidity. We have found that MERS-CoV pathogenesis is exacerbated in a mouse with pre-existing diabetes. We will determine the mechanism for this enhanced disease by determining the role of the changes in lung architecture, and immune response. In Aim1 we will determine whether accessibility of the Type 2 alveolar cells, the target cells for MERS-CoV in the alveoli, is increased in diabetic mice compared to normal mice. Our data suggests that at the earliest points of infection, the alveoli are highly susceptible to MERS- CoV but normal mouse Type 2 alveolar cells are not. We will evaluate the mucus and architecture of the lungs to determine if there is a difference that could explain the differential infection. In Aim 2, we will determine if the immune response in diabetic mice is different than normal mice. A difference in the immune response, especially innate immune response, could explain the susceptibility differences in diabetic and normal mice. In Aim 3 we will determine whether therapeutics that are effective in normal mice are deficient in diabetic mice with the goal of altering those therapeutics in the future for more effective therapies for comorbid patients. Together this proposal will determine why diabetic mice and potentially humans are highly susceptible to MERS-CoV.", "keywords": [ "Alveolar", "Alveolar Cell", "Animal Model", "Antiviral Agents", "Antiviral Therapy", "Architecture", "Carbohydrates", "Case Fatality Rates", "Case Study", "Cell surface", "Cells", "Cessation of life", "Clinical", "Complex Mixtures", "Coronavirus", "Coronavirus Infections", "Data", "Diabetes Mellitus", "Diabetic mouse", "Diet", "Disease", "Disease Outbreaks", "Disease Outcome", "Effectiveness", "Exhibits", "Future", "Glare", "Goals", "Health Personnel", "Heart Diseases", "High Fat Diet", "Human", "Immune", "Immune response", "Immunosuppression", "Infection", "Inflammatory", "Innate Immune Response", "Kidney Failure", "Kinetics", "Knowledge", "Lead", "Link", "Lung", "Lung Inflammation", "Lung diseases", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Monoclonal Antibodies", "Morbidity - disease rate", "Mucous Membrane", "Mucous body substance", "Mus", "Non-Insulin-Dependent Diabetes Mellitus", "Pathogenesis", "Pathogenicity", "Pathway interactions", "Patients", "Persons", "Poly I-C", "Predisposition", "Production", "Proteins", "Public Health", "Respiratory System", "Risk", "Role", "Saudi Arabia", "South Korea", "Structure", "Surface", "Therapeutic", "Time", "Treatment Efficacy", "Vaccines", "Virion", "Virus", "Virus Diseases", "Work", "anti-viral efficacy", "chemokine", "comorbidity", "comparative", "cytokine", "diabetic", "diabetic patient", "effective therapy", "experimental study", "in vivo", "influenza virus vaccine", "microbial", "mortality", "mouse model", "novel", "pathogen", "permissiveness", "receptor", "respiratory infection virus", "respiratory virus", "response", "targeted treatment" ], "approved": true } }, { "type": "Grant", "id": "8982", "attributes": { "award_id": "4R44AG071388-02", "title": "Development of a stress kinase inhibitor therapeutic candidate for Alzheimer's Disease and related dementia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 7276, "first_name": "AKANNI YAO", "last_name": "Clarke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-30", "end_date": "2024-04-30", "award_amount": 1175175, "principal_investigator": { "id": 23459, "first_name": "Wayne F", "last_name": "Anderson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1606, "ror": "", "name": "NEUROKINE THERAPEUTICS, LLC", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23460, "first_name": "LAWRENCE S", "last_name": "HONIG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1606, "ror": "", "name": "NEUROKINE THERAPEUTICS, LLC", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "There is an urgent need for disease modifying therapeutic approaches to Alzheimer’s disease, a major health crisis that lacks disease modifying therapies. Neurokine Therapeutics (NKT) has a unique phase 2 ready clinical asset, MW01-18-150SRM (= MW150), that represents a paradigm shift from the field’s dominant focus on amyloid pathway targeted therapeutic candidates. MW150 has a unique portfolio of target recognition and engagement, preclinical and clinical safety, and orally bioavailable drug exposure. The portfolio provides rational explanations for some of the off-target effects, adverse pharmacology, and clinical challenges encountered with prior art in the same therapeutic class, only one of which exhibited brain exposure. Therefore, NKT seeks to rapidly fill a key gap for clinical development and future commercialization through leveraging of the NIA SBIR program. Even with covid-19 pandemic delays, NKT anticipates an exceptional phase 2a ready portfolio before the potential start date of a Fast Track SBIR investment by NIA. MW150 development was based on the perspective that Alzheimer’s and related diseases are disorders of progressive synaptic dysfunction with a common neuroinflammation component. Therefore, our novel approach to disease modifying therapeutic intervention was to target pathophysiology progression pathways, with the neuroinflammation-synaptic dysfunction axis being an underlying element across multiple diseases. The activity of the druggable serine/threonine protein kinase, p38alphaMAPK is increased in both neurons and glia, raising the potential for efficacy through a novel pleiotropic pharmacological mechanism in which a single molecular target drug is modulated in distinct cellular pathophysiology processes. Our specific aims are: Aim 1, Generate, qualify and transfer to the Columbia University (CU) site drug product and placebo capsules. Commercial scale drug substance is on hand, GMP drug product batch processes are established and CU has an experienced and qualified Research Pharmacy; Aim 2A, Prepare, recruit, and conduct a phase 2a clinical study of MW150. We will study 24 Alzheimer’s patients, randomized to once daily administration of test article (MW150: 42 and 84 mg) or placebo (3:1 ratio); Aim 2B. Evaluate safety and pharmacokinetics and monitor response biomarkers. Key milestones for SBIR part I deal with delivery of sufficient validated drug product to the clinical site research pharmacy. Key milestones for part II deal with clinical treatment and evaluations of safety and PK. Outcomes will fill a critical gap in MW150’s commercial and clinical development portfolio as well as provide a firm foundation required for follow-on phase 2b studies in Alzheimer’s Disease. The potential longer-term impact would be filling a void in safe, disease modifying therapeutics for a set of related neurologic disorders.", "keywords": [ "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease patient", "Alzheimer&apos", "s disease related dementia", "Amyloid", "Arts", "Bioavailable", "Brain", "COVID-19 pandemic", "Clinical", "Clinical Research", "Clinical Treatment", "Development", "Disease", "Drug Exposure", "Drug Kinetics", "Elements", "Exhibits", "Foundations", "Functional disorder", "Future", "Hand", "Health", "Investments", "Monitor", "Neuroglia", "Neurons", "Oral", "Outcome", "Pathway interactions", "Pharmaceutical Preparations", "Pharmacology", "Pharmacy facility", "Phase", "Placebos", "Process", "Protein-Serine-Threonine Kinases", "Randomized", "Research", "Safety", "Site", "Small Business Innovation Research Grant", "Synapses", "Testing", "Therapeutic", "Therapeutic Intervention", "Universities", "base", "capsule", "clinical development", "clinical research site", "commercialization", "experience", "kinase inhibitor", "molecular drug target", "nervous system disorder", "neuroinflammation", "novel", "novel strategies", "pre-clinical", "programs", "recruit", "research clinical testing", "response biomarker", "stress kinase", "targeted treatment", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "7607", "attributes": { "award_id": "3P30AG066512-01S1", "title": "Alzheimer's Disease Research Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 11650, "first_name": "Cerise", "last_name": "Elliott", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-01", "end_date": "2025-04-30", "award_amount": 348851, "principal_investigator": { "id": 21378, "first_name": "THOMAS M", "last_name": "WISNIEWSKI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker development. Here we propose to continue this long-standing successful research direction with a focus on understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline. The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias (ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach, Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component [REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores, with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel avenues of investigation with methodological developments by the cores (via innovative cognitive assessments, neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary, the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, this focus will be expanded by: 1) improving our understanding of disease heterogeneity; 2) identifying new biomarkers that will allow early detection; and 3) fostering research that will develop effective therapeutic interventions.", "keywords": [ "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Amyloid", "Area", "Autopsy", "Behavioral", "Biological Assay", "Biological Markers", "Cerebrospinal Fluid", "Clinical", "Clinical Data", "Cognitive", "Collaborations", "Communities", "Counseling", "Cyclotrons", "Data Linkages", "Data Set", "Dementia", "Development", "Diagnosis", "Diagnostic Services", "Early Diagnosis", "Education", "Fostering", "Funding", "Goals", "Health", "Heterogeneity", "Impaired cognition", "Infrastructure", "Intervention", "Investigation", "Laboratories", "Magnetic Resonance Imaging", "Measures", "Mental Depression", "Methodology", "Mission", "Neuropsychology", "New York", "Participant", "Pathology", "Patients", "Performance", "Phenotype", "Plasma", "Population", "Positron-Emission Tomography", "Proteomics", "Psychological Impact", "Radiochemistry", "Research", "Role", "Scanning", "Scientist", "Secure", "Statistical Data Interpretation", "Stress", "Techniques", "Therapeutic Intervention", "Time", "Training", "Training and Education", "Translational Research", "Treatment Efficacy", "Universities", "Update", "Work", "aged", "aging brain", "biomarker development", "cognitive function", "cognitive testing", "community setting", "data management", "disease heterogeneity", "education research", "epidemiology study", "improved", "in vivo", "induced pluripotent stem cell", "innovation", "mild cognitive impairment", "neuroimaging", "neuroimaging marker", "neuropathology", "next generation", "normal aging", "novel", "novel marker", "novel therapeutic intervention", "outreach", "posters", "prevent", "programs", "psychosocial", "recruit", "social factors", "sociodemographic variables", "tau Proteins" ], "approved": true } }, { "type": "Grant", "id": "6446", "attributes": { "award_id": "3R01MH120597-02S1", "title": "Adapting Coordinated Specialty Care in the Post COVID-19 Era", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21652, "first_name": "Matthew V.", "last_name": "Rudorfer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-08-15", "end_date": "2024-07-31", "award_amount": 324329, "principal_investigator": { "id": 21653, "first_name": "LISA B.", "last_name": "DIXON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 21654, "first_name": "Jennifer", "last_name": "Humensky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 812, "ror": "", "name": "NEW YORK STATE PSYCHIATRIC INSTITUTE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Coordinated Specialty Care (CSC) programs provide evidence-based services for young people with recent onset of a psychotic disorder. New York State's program, OnTrackNY is a nationally recognized model of CSC treatment. OnTrackNY provides coordinated, team-based services and has demonstrated improvements in symptoms, functioning, hospitalization, and work/school participation. The rapid rise of COVID-19 has created shocks to the health care system, producing numerous rapid changes in behavioral health service delivery, including telehealth, in the absence of guidance from evidence or experience. It is unclear how these changes will impact the need for and delivery of psychiatric care and client outcomes. OnTrack Central, an intermediary organization responsible for training and implementation support of OnTrackNY programs, has created systems for multi-level stakeholder engagement, a centralized data collection protocol for quality improvement and evaluation of program fidelity, and a mechanism to support practice based-research. Our daily engagement of the OnTrackNY network has revealed how recent changes are dramatically impacting CSC services. In 2019, OnTrackNY was awarded a hub within the Early Psychosis Intervention Network (EPINET) to advance a learning health care system (LHS). The breadth of OnTrackNY sites coupled with OnTrack Central oversight provides an opportunity to examine the impacts of the COVID-19 crisis in New York State. The diversity of the 23 OnTrackNY teams located throughout the state enables examination of settings with high and low prevalence of COVID-19 infections and diverse regulatory and workforce environments. The OnTrackNY network includes programs that operate within variable regulations (outpatient clinics at community agencies, state-operated facilities, and community and academic hospitals in urban, suburban, and rural areas) with very diverse participant populations. This project will examine the implications of modifications to service delivery within the OnTrackNY LHS during and after the COVID-19 crisis. We will use the implementation science framework, Framework for Reporting Adaptations and Modifications-Enhanced (FRAME) to systematically evaluate modifications made and ascertain their impact. We will utilize integrative mixed methods, including qualitative interviews and focus groups with stakeholders (clients, families, providers and decision makers at the state and local levels) and analysis of OnTrackNY program data The project aims to assess: 1) the implications of governmental and agency level policy changes and how these decisions impact team staffing and functioning; 2) implications for delivery of CSC services; and 3) impact on client-level care processes (e.g. utilization of services) and outcomes. The goal is to develop a CSC Model Adaptation Guide that will be fidelity-consistent, and associated with consistent engagement, service utilization or favorable outcomes of care.", "keywords": [ "Ambulatory Care Facilities", "Appointment", "Award", "Businesses", "COVID-19", "Caring", "Characteristics", "Client", "Code", "Cognitive deficits", "Communities", "Coupled", "Creativeness", "Data", "Data Collection", "Decision Making", "E-learning", "Education", "Effectiveness", "Employment", "Enrollment", "Environment", "Family", "Family member", "Focus Groups", "Goals", "Government Agencies", "Health Services", "Healthcare Systems", "High Prevalence", "Hospitalization", "Hospitals", "Infection", "Infrastructure", "Intervention", "Interview", "Learning", "Location", "Low Prevalence", "Medical", "Medication Management", "Methods", "Modeling", "Modification", "Needs Assessment", "Neurobehavioral Manifestations", "New York", "Outcome", "Participant", "Penetration", "Persons", "Phase", "Policies", "Population", "Practice based research", "Process", "Program Evaluation", "Protocols documentation", "Provider", "Psychiatric therapeutic procedure", "Psychotherapy", "Psychotic Disorders", "Regulation", "Reporting", "Risk Factors", "Schools", "Services", "Shock", "Site", "Subgroup", "Supported Employment", "Symptoms", "System", "Technology", "Time", "Training", "Work", "base", "behavioral health", "care outcomes", "care systems", "evidence base", "experience", "health care delivery", "implementation science", "innovation", "loved ones", "medical specialties", "outreach", "peer", "programs", "racial and ethnic disparities", "rural area", "service delivery", "service utilization", "suburb", "suicidal risk", "telehealth", "trend" ], "approved": true } }, { "type": "Grant", "id": "9356", "attributes": { "award_id": "3R21TW010789-02S1", "title": "Soweto Syndemics: A Two-Phase Study of Surveillance and Co-Morbid Experiences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Fogarty International Center (FIC)" ], "program_reference_codes": [], "program_officials": [ { "id": 10854, "first_name": "MARYA", "last_name": "LEVINTOVA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-10-01", "end_date": "2021-02-28", "award_amount": 31500, "principal_investigator": { "id": 25107, "first_name": "Emily A", "last_name": "Mendenhall", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 181, "ror": "https://ror.org/05vzafd60", "name": "Georgetown University", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 181, "ror": "https://ror.org/05vzafd60", "name": "Georgetown University", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "The parent award was the first to test the theory of syndemics among a vulnerable population. The syndemics concept, in contrast to the epidemics concept, combines concepts of “synergy” with “epidemic” to investigate how 1) two or more diseases cluster together within a population, 2) these diseases interact, often biologically, and 3) large-scale social forces precipitate them. Syndemic clusters with Type 2 diabetes (T2DM) among black South Africans exemplify the syndemics concept, and in-depth investigation of this phenomenon provides important policy and clinical perspectives. The parent study established a cohort to evaluate syndemic clusters in Soweto, South Africa. The cohort study was organized around two phases: phase 1 focused on surveillance of co-occurring social and medical conditions in Soweto, and phase 2 explored people’s experiences living with co-occurring conditions. We completed 957 interviews for Phase 1, documenting prevalence and clustering of social and medical conditions in Soweto; although, we cut short recruitment for Phase 1 to safeguard against risk of transmission. We quickly transformed our methods to phone interviews with our existing cohort to focus on knowledge, perceptions, and experiences related to COVID-19 and depressive risk. Thus, from Phase 1, we have extensive data not only on COVID-19 but also on preexisting social stress, psychiatric morbidity, and comorbid medical conditions that will great advance our understanding of the novel coronavirus. Current COVID-19 data involves 1) perceptions of risk, morbidity, and transmissibility; 2) social, economic, and psychological predictors of COVID-19 through longitudinal design; and 3) effects of COVID-19 and comorbidities common in South Africa (e.g. HIV, diabetes, hypertension, depression). We also conducted 100 in depth qualitative interviews with people living with diabetes and comorbid infection (HIV and TB), hypertension, and depression. Once quarantine is lifted, we hope to complete 50 more in depth interviews, with an additional section on COVID-19. We also plan to conduct follow up phone interviews with each individual in the cohort to investigate how people are doing six months from now and to administer a brief mental health inventory. We will invite 250 participants into the research center to collect blood samples to evaluate stress and inflammation—which will take on even more significance if coronavirus eventually spreads throughout Soweto. These amendments have been approved by the Human Research Ethics Committee at the University of the Witwatersrand in Johannesburg, South Africa. Analysis: Now that we have completed baseline data collection we are beginning to analyze data from the parent study. The first hypothesis that social and economic determinants of co-occurring conditions will differ from those determinants that foster singular disease apart from syndemic clusters will be evaluated within the next month. The second aim to investigate social and medical experiences and health care behaviors will be completed in part by late summer 2020; we have begun to code existing qualitative data but need more interviews to complete our analysis. We are actively coding the COVID data, as well, with nearly 300 interviews complete.", "keywords": [ "Amendment", "Award", "Behavior", "Biological", "Blood specimen", "COVID-19", "Clinical", "Code", "Cohort Studies", "Coronavirus", "Data", "Data Collection", "Diabetes Mellitus", "Disease", "Disease Clusterings", "Economics", "Epidemic", "Equipment and supply inventories", "Fostering", "HIV", "HIV/TB", "Healthcare", "Human Research Ethics", "Hypertension", "Immunity", "Individual", "Infection", "Inflammation", "Interview", "Investigation", "Knowledge", "Lifting", "Medical", "Mental Depression", "Mental Health", "Methods", "Morbidity - disease rate", "Non-Insulin-Dependent Diabetes Mellitus", "Parents", "Participant", "Perception", "Phase", "Policies", "Population", "Prevalence", "Quarantine", "Research", "Research Ethics Committees", "Risk", "Sampling", "Serologic tests", "Social Distance", "South Africa", "South African", "Stress", "Telephone", "Testing", "Universities", "Vulnerable Populations", "cohort", "comorbidity", "coronavirus disease", "depressive symptoms", "economic determinant", "experience", "follow-up", "longitudinal design", "novel coronavirus", "pandemic disease", "physical conditioning", "psychologic", "recruit", "risk perception", "social", "social determinants", "social stress", "surveillance study", "synergism", "theories", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "7782", "attributes": { "award_id": "1ZIABC011872-02", "title": "PSMA-PET Imaging of High Risk Prostate Cancer-Cures", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 1116551, "principal_investigator": { "id": 23588, "first_name": "peter L", "last_name": "choyke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1601, "ror": "", "name": "DIVISION OF BASIC SCIENCES - NCI", "address": "", "city": "", "state": "", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1601, "ror": "", "name": "DIVISION OF BASIC SCIENCES - NCI", "address": "", "city": "", "state": "", "zip": "", "country": "United States", "approved": true }, "abstract": "This study has now started accrual. It is a multi-institutional trial involving the use of PSMA PET/CT in high risk patients. The PSMA PET agent, F18 DCFPyl, is provided to sites by Progenics. The American College of Radiology will assist in archiving imaging and pathology. Approximately 4 patients have been accrued at the NCI site to date and accrual was interrupted by the COVID pandemic. To date we have seen excellent performance of the PSMA PET agent and the surgery has been successfully performed without incident.", "keywords": [ "American College of Radiology", "FOLH1 gene", "Funding", "Interruption", "Malignant neoplasm of prostate", "Operative Surgical Procedures", "PET/CT scan", "Pathology", "Patients", "Performance", "Positron-Emission Tomography", "Protocols documentation", "Recurrence", "Scanning", "Site", "Testing", "Time", "coronavirus disease", "high risk", "image archival system", "pandemic disease", "prostate cancer risk" ], "approved": true } }, { "type": "Grant", "id": "10564", "attributes": { "award_id": "1R03HD107047-01A1", "title": "Data Archiving and Dissemination for Comparative Population Science", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9683, "first_name": "REGINA M", "last_name": "BURES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-08-31", "award_amount": 82250, "principal_investigator": { "id": 26581, "first_name": "Sabrina", "last_name": "Hermosilla", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The creation of large, scientific studies of human behavior, social experience, and health in the general population form the cornerstone of data creation investments of the past five decades. Because the data from these studies are essential for the construction and evaluation of public policies and programs to improve the health and wellbeing of the population, NICHD places a high scientific priority on dissemination activities and tools that significantly expand the scientific use of such data. A key limitation of these dissemination efforts, thus far, is a relative dearth of data from non-U.S. populations. Dissemination of rigorous non-U.S. population data resources are urgently needed to quickly and easily test the breadth of external validity of key social, behavioral, and public health findings. We leverage NICHD’s long-term investment in the Chitwan Valley Family Study (CVFS) in Nepal to achieve this high-priority objective. The CVFS is an excellent comparative data resource, featuring a 25-year panel study from Nepal with many important features. First, the CVFS was designed to replicate features from the best longitudinal studies, such as the Panel Study of Income Dynamics and the British Household Panel Survey. Second, it was designed to measure change over time in the community level, as opposed to the individual and household levels alone. Third, the CVFS measures environmental change over time. Fourth, the CVFS follows all migrants (both individuals and households), no matter where they move, and periodically refreshes the sample with in-migrants. Finally, the CVFS has newly collected saliva-based DNA samples from all family members, blood-based anemia screening for all children, and COVID-19 disruption data on all households. Though CVFS content originally focused on family and fertility, it now includes measures from domains such as child and adolescent health. The CVFS is thus an unparalleled resource for studying NICHD priorities. We will transform access to this special resource with changes focused on use of the CVFS data, measures specially designed to facilitate comparisons, construction of new data files to speed data linking and data analysis, construction of new learning tools, and new web-based analysis tools. The activities are specifically designed to improve the transparency of comparability between CVFS and data from other settings to assist scientists making these comparisons. We will also improve data quality and user experience so the complexity of these multilevel, 25-year, multi-topic data is not an obstacle to data use. Unmatched in longevity, breadth, and its multilevel (individual, household, community) structure, the CVFS is an ideal resource for international comparative research and model testing that advances the scientific understanding of many high-priority social, behavioral, and health science questions.", "keywords": [ "American", "Anemia", "Archives", "Award", "Behavior", "Behavioral Sciences", "Blood", "British", "COVID-19", "Child", "Child Health", "Communities", "Complex", "DNA", "Data", "Data Analyses", "Data Files", "Data Set", "Demography", "Evaluation", "Family", "Family Study", "Family member", "Fertility", "Funding", "General Population", "Health", "Health Sciences", "Household", "Human", "Individual", "International", "Investments", "Journals", "Learning", "Link", "Longevity", "Longitudinal Studies", "Measures", "Migrant", "Modeling", "Modernization", "National Institute of Child Health and Human Development", "Nepal", "Online Systems", "Outcome", "Paper", "Peer Review", "Personal Satisfaction", "Population", "Population Sciences", "Public Health", "Public Policy", "Publishing", "Research", "Research Personnel", "Resources", "Saliva", "Sampling", "Scientific Advances and Accomplishments", "Scientist", "Series", "Services", "Social Sciences", "Sociology", "Speed", "Structure", "Surveys", "Testing", "Time", "Western Europe", "adolescent health", "adolescent health outcomes", "archive data", "base", "behavioral health", "comparative", "data archive", "data dissemination", "data quality", "data resource", "data sharing", "data tools", "design", "environmental change", "experience", "improved", "innovation", "panel study of income dynamics", "programs", "response", "screening", "social", "study population", "support tools", "tool", "usability", "web site" ], "approved": true } }, { "type": "Grant", "id": "8124", "attributes": { "award_id": "1R43GM140807-01", "title": "Fizz Reader: Interactive Accessible Data Visualizations Through an NLG Interface", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23999, "first_name": "Edgardo", "last_name": "Falcon-Morales", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-03-02", "end_date": "2022-08-31", "award_amount": 175784, "principal_investigator": { "id": 24000, "first_name": "Douglas Alan", "last_name": "Schepers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1683, "ror": "", "name": "FIZZ STUDIO LLC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1683, "ror": "", "name": "FIZZ STUDIO LLC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Specific Aims There are many modern approaches to accessibility in data visualizations, from simple but inadequate alternative data tables to excellent work with tactile graphics, haptics, and sonification. Each has its benefits and limitations, but common underlying weaknesses to the advanced methods are lack of precision and need for reader training. By contrast, most of the 7.7 million Americans with visual disabilities are at least moderately skilled in using a screen reader. However, this typically limits users to serial data point access, the equivalent of a data table, which does not provide an equivalent experience to the advantages of data visualizations. It decreases independence and professional opportunities, increases stress, decreases quality of life, and puts vulnerable people at risk when crucial public health information is disseminated in graphical-only form, such as in the current COVID-19 pandemic. The long range goal of this Phase I project is to create technologies that permit authors and developers of web sites to effortlessly publish charts, diagrams, and infographics that are fully usable by all people, in particular people who are blind, low-vision, or have cognitive disabilities. In this Phase I SBIR project, we will assess the feasibility of creating interactive contextual automatic descriptions that enable the reader to construct an accurate working mental model of the data with minimal effort and time, to perform tasks and make decisions. Fizz Studio has created a software package, Fizz Charts, that generates accessible keyboard-browsable charts for use on any website. We seek to enhance this with Fizz Reader, a novel interactive interface that uses natural language generation (NLG) to enable the user to query the chart for quick answers about each data point, its relationship to other data points and to the chart statistics, and to high-level or detailed trends and patterns in the data. The effect is of one person explaining the chart to another over the phone, and providing relevant and rapid answers to help the listener understand as much of the data as they wish for a core set of 7 common chart types: bar; line; pie; histogram; scatterplot; heatmap; and flowchart. Aim 1: Develop effective interactive NLG model and engine module To concisely communicate relevant details to the user, we will design a comprehensive set of tasks for all supported chart types, and a set of NLG templates for each chart component (e.g. data point, axis, title). We will use these NLG templates to develop a software module which composes colloquial utterances from an internal statistical data model we build from the data extracted from the chart. Each set of options will represent the affordances optimal for the chart type (e.g. comparisons for bar charts, changes over time for line charts). This module will have a client-server API architecture, to make it adaptable to multiple user interface modalities, including the screen reader intermediary in Aim 2, as well as a standalone digital assistant or a component in a smart speaker. To ensure effectiveness and clarity, we will perform multi-phase testing for usability and task accomplishment with 10-20 blind and low-vision human subjects, and integrate their feedback. We seek 80% successful task accomplishment across all chart types and tasks. Aim 2: Implement a browser-based screen reader intermediary User Interface Module (UIM) To integrate our NLG module directly into the browser, for on-demand presentation of the generated NLG chart information to users of screen readers, we will implement an option-based interface using JavaScript and ARIA technologies. Each set of options will be context-dependent on the currently focused item (e.g. data point, axis, title), and will reflect the optimal tasks for that item in that specific chart type, to enable users to use keyboard input to select from a virtual dropdown of options, and the results will be returned as text to be presented by the screen reader or braille display. We will use a Lean development methodology to test for 95% interoperability across common browsers, operating systems, mobile devices, and screen readers. Conclusion and goals for Phase II The purpose of this Phase I grant is to significantly advance the state of the art for the accessibility of data charts for people with visual disabilities to aid them in their personal and professional lives. In Phase II, we will build on this foundation to support more complex diagram types including schematics, refine the UI for more operations, and explore other deployments such as smart speakers, browser extensions, or app plugins.", "keywords": [ "American", "Architecture", "Braille Display", "COVID-19 pandemic", "Client", "Complex", "Computer software", "Data", "Decision Making", "Development", "Effectiveness", "Ensure", "Feedback", "Flowcharts", "Foundations", "Generations", "Goals", "Grant", "Methodology", "Methods", "Modality", "Modeling", "Modernization", "Operating System", "Pattern", "Persons", "Phase", "Psyche structure", "Public Health", "Publishing", "Quality of life", "Reader", "Risk", "Small Business Innovation Research Grant", "Stress", "Tactile", "Technology", "Telephone", "Testing", "Text", "Thinness", "Time", "Training", "Visual", "Visual impairment", "Work", "base", "blind", "cognitive disability", "data modeling", "data visualization", "design", "disability", "experience", "handheld mobile device", "haptics", "human subject", "intelligent personal assistant", "interoperability", "natural language", "novel", "operation", "statistics", "trend", "usability", "virtual", "web site" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1419, "count": 14184 } } }